TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Repeated TMS at Low Frequencies to Reduce Seizure Occurrence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Long-term protocol:~Inclusion Criteria:~* Experience ≥ 3 seizures/month in the month prior to starting study (any type of seizure will count)~* No status epilepticus in the last 12 months~* No change in medication in last 30 days~Exclusion Criteria:~* Presence of implanted electronic devices (e.g., pacemaker, medication pump, brain or vagus nerve stimulator, cochlear implant)~* Presence of intracranial metal (e.g., aneurysm clip)~* Unable to cooperate with non-sedated, navigated TMS testing~Short-term protocol:~Inclusion Criteria:~* Epilepsia partialis continua or status epilepticus~* At least 2 medications failed~* At least 24 hours of acute phase~Exclusion Criteria:~* Presence of implanted electronic devices (e.g., pacemaker, medication pump, brain or vagus nerve stimulator, cochlear implant)~* Presence of intracranial metal (e.g., aneurysm clip)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: Weekly TMS (Type: EXPERIMENTAL): LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days) , LF-rTMS 1 session/week for 1 month (4 days), and LF-rTMS 1 session/month for 11 months
- Group 2: Monthly TMS (Type: EXPERIMENTAL): LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days), LF-rTMS 1 session/month for 12 months
- Group 3: Sham TMS (Type: SHAM_COMPARATOR): Sham LF-rTMS for 2 weeks (5 days per week for a total of 10 days), sham LF-rTMS 1 session/week for 1 month (4 days), and sham LF-rTMS 1 session/month for 1 month. After the sham stimulation real LF-rTMS intervention sessions will be delivered as follows: 50% of placebo group will follow group 1 protocol and the other 50% will follow group 2 protocol
- Short-term protocol (Type: EXPERIMENTAL): LF-rTMS intervention daily for up to 5 days in medically refractory status epilepticus participants only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TAP Block for Open Radical Prostatectomy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 years and over~* ASA class 1, 2~* Elective open radical prostatectomy~Exclusion Criteria:~* Any history or signs of cardiac, hepatic and renal failure. Patients with raised serum LFTs and serum creatinine outside normal range~* Any chronic use of opioid analgesic~* Morbid obesity (BMI\>40)~* History of allergic reactions to any of the study medications and the medications used for the trial~* Pregnancy~* Previous abdominal surgery

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): group A (control) will receive a bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side) via both TAP catheters.The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
- TAP (Type: EXPERIMENTAL): group B (TAP) will receive a bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side) via TAP catheters. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Health Costs and Resource Utilization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males 18 years of age or older who are not receiving azathioprine or 6 mercaptopurine.~* Non-pregnant, non-lactating females, 18 years of age or older.~* Females of child bearing potential must have a negative serum pregnancy test prior to randomization, and must use a hormonal (oral, implantable or injectable) or barrier method of birth control throughout the study. \[defined as a minimum of one year since the last menstrual period\]).~* Documented diagnosis of CD or UC.~* Active disease symptoms at visit 1 defined by: a. CD subjects: HBS \~ 6 UC subjects: PMCS \~ 4.~* Current infliximab therapy (naive to adalimumab) or current adalimumab therapy (naive to infliximab ).~* A minimum of 13 weeks of infliximab or adalimumab treatment prior to visit 1 at the following dose:~* Stable dose of azathioprine, 6 mercaptopurine, methotrexate, and/or 5-aminosalicylates in the 4 weeks prior to visit 1.~Exclusion Criteria:~* Contraindication to the use of either infliximab or adalimumab.~* Current infliximab treatment but not naive to adalimumab or~* Current adalimumab treatment but not naive to infliximab.~* Infliximab dosing prior to visit 1 was not 5 mg/kg at weeks 0, 2 and 6 and then q8w.~* Adalimumab dosing prior to visit 1 was not 160 mg at week 0, 80 mg at week 2, and then 40 mg q2w.~* Received any investigational drug within 30 days prior to visit 1.~* Serious underlying disease other than CD or UC which in the opinion of the investigator may interfere with the subject's ability to participate fully in the study.~* History of alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures.~* Stools positive for clostridium difficile.~* Pregnant or lactating women.~* Change in dose of azathioprine, 6 mercaptopurine, methotrexate, and/or 5-aminosalicylates in the 4 weeks prior to visit 1.~* Males 22 years of age or less who are receiving azathioprine or 6 mercaptopurine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empiric Dose Intensification (Type: ACTIVE_COMPARATOR): Intensify treatment with the existing drug
- Testing based strategy (Type: ACTIVE_COMPARATOR): Measurement of drug (Adalimumab/Infliximab) Testing-based strategy for the management of secondary loss of response that is based on drug/ ADA measurement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacologically-based Strategies for Opioid Substitution Therapy During Pregnancy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. On a stable dosing regimen of BUP for at least 2 weeks as part of an established medication- assisted treatment (MAT) program.~2. Willingness to undergo supervised dose reduction~3. Subject willingness to be assigned to either the Magnitude, or Frequency group.~4. Single gestation between 14-30 weeks at the initiation of the dose reduction~5. On a BUP dose between 6- 24 mg daily (lower doses will not provide sufficient data points)~6. Willingness to have urine samples tested for drugs of abuse and blood samples tested for BUP+M concentrations during the Medical Supervised Withdrawal (MSW) clinic appointments~7. Willingness to attend weekly or biweekly MSW clinic appointments and to have daily contact via text messaging and to complete daily logs of sleep quality, withdrawal symptoms and symptoms of craving.~8. Willingness to attend psychosocial support meetings as needed.~Exclusion Criteria:~1. Current use of cocaine, heroin, benzodiazepines, barbiturates, phencyclidine (PCP), or opioids other than BUP.~2. Currently taking more than two mental health medications~3. Active moderately severe depression (PHQ-9 score ≥15 or suicidal ideation)~4. Current incarceration~5. Lack of a phone or transportation to and from clinic~6. Major fetal malformation~7. Mother with significant vaginal bleeding or serious medical or obstetrical complication that could adversely affect the study~8. Planned delivery at another institution~9. HIV or AIDS~10. Diagnosis of schizoaffective disorder or psychosis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Magnitude Group (Type: ACTIVE_COMPARATOR): Subjects will receive alternating reductions of 1 mg or 2 mg weekly.
- Frequency Group (Type: ACTIVE_COMPARATOR): Subjects will receive dose reductions of 2 mg on alternating intervals of 1 and 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage IIIB (with effusion) or Stage IV NSCLC any histology~* No prior chemotherapy~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1~* Greater than or equal to 18 years of age~* Life expectancy at least 12 weeks~* Adequate bone marrow, liver and renal function~Exclusion Criteria:~* Prior systemic anti cancer therapy~* Known brain metastasis. Patients with neurological symptoms should undergo at computed tomography (CT) scan/magnetic resonance imaging (MRI) of the brain to exclude brain metastasis~* Pulmonary hemorrhage/bleeding event \> Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 within 4 weeks of first dose of study drug~* Thrombotic or embolic events including Transient ischemic attack (TIA) within the past 6 months~* Uncontrolled hypertension~* Any other hemorrhage/bleeding event \> CTCAE Grade 3 within 4 weeks of first dose of study drug~* Major surgery within 4 weeks~* Evidence or history of bleeding diathesis or coagulopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib + C/P (Type: EXPERIMENTAL): Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), \[400 mg orally, twice daily\] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
- Placebo + C/P (Type: ACTIVE_COMPARATOR): Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily\] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: NIBP (Non-invasive Blood Pressure) Algorithm Enhancements (Characterize the Robustness of Motion Artifact Suppression)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Obstetric patient at Yale New Haven Hospital~* Receiving epidural anesthesia~* Age at least 18 years~* Willing and able to provide informed consent in a Sponsor approved language~* Willing and able to comply with study-related procedures~* Priority classification II, III, or IV~Exclusion Criteria:~* Non-caesarian section deliveries~* Ruptured uterus, prolonged fetal bradycardia, cord prolapse, or other emergent condition~* Procedures under general anesthesia~* Altered mental status~* Currently participating in another clinical trial with any product, treatment and/or medication that clinically interferes with the study endpoint(s)~* Priority classification I or V

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caesarian Section Patient (Type: None): Obstetric patient

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic pelvic pain (\>6 months) perceived to be related to the urinary bladder and accompanied by urinary symptoms such as frequent urination during the day and/or night, and/or urgency to void~* Total score of 8 or greater on the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI)~* The mean of the average pain intensity scores at screening phase \>=5 (on a scale of 0 to 10)~* Medically stable~Exclusion Criteria:~* Urinary culture is positive for a urinary tract infection; Recent invasive therapy to the bladder~* History or current conditions indicating that the bladder pain can be caused by diagnoses other than IC/PBS (eg, pain caused by a confirmed or suspected neoplasm)~* History of malignancy within the past 2 years, with the exception of basal cell carcinoma that has been successfully treated~* Women who are pregnant or breast-feeding~* A body mass index (BMI) of \>39 kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- JNJ-42160443 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Survey on Chinese Medicine Syndrome for Patients With Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* newly suspected / diagnosed NSCLC patients from Department of Cardiothoracic Surgery and going to have resection~* age of 18 or above~* without prior therapy for NSCLC, including surgery, chemotherapy, radiation therapy and Chinese herbal medicine~* patients who can read and speak Chinese~Exclusion criteria:~* history of prior therapy for NSCLC~* history of concurrent or prior malignancy~* with concurrent open tuberculosis or inflection~* unable to communicate (e.g. cognitive impairment)~* psychiatric or addictive disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NSCL cancer patients (Type: None): Surgery, chemotherapy and/or radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-60~* Healthy nulliparous or multiparous women~* Term (\>36 week gestation)~* Singleton pregnancy~* Spontaneous labor or with spontaneous rupture of membranes~* Receive oxytocin~* Request neuraxial analgesia~Exclusion Criteria:~* Under 18 years of age~* Presence of any systemic disease (e.g., diabetes mellitus, hypertension, preeclampsia)~* Use of chronic analgesic medications~* Prior administration of systemic opioid labor analgesia~* Non-vertex presentation~* Induction of labor~* Contraindication to neuraxial analgesia.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient is positioned for epidural placement. Oxytocin management continued as per protocol.
- Group B (Type: EXPERIMENTAL): An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
- Group C (Type: ACTIVE_COMPARATOR): The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
- Group D (Type: EXPERIMENTAL): The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement was halved and not increased for 60 minutes until after placement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suspected or confirmed COVID19 infection~* Bilateral Infiltrates on CXR~* SpO2 \<94% on FiO2 40% by either venturi facemask or high flow nasal cannula~* RR \<40~* Written informed consent~Exclusion Criteria:~* Age \<18~* Uncooperative or likely to be unable to lie on abdomen for 16 hours~* Receiving comfort care only~* Multi-organ failure~* RR\>40~* Contraindication to PP (e.g. vomiting, abdominal wound, unstable pelvic/spinal lesions, pregnancy \>20/40 gestation, severe brain injury).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prone Positioning (Type: EXPERIMENTAL): Intervention patients will remain up to 16 hours per day in Prone Positioning with 45 minutes breaks for meals
- Standard Care (Type: ACTIVE_COMPARATOR): Control patients will receive full standard care. Prone Positioning as a rescue intervention is permitted and is recorded.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18-year-old~* Patients suffering from a neoplastic disease for which treatment protocol includes Cisplatin.~Exclusion Criteria:~* Women of childbearing potential pregnant or with intention to become pregnant within the trial duration~* Women who are breastfeeding~* Pathological findings on otoscopy that do not allow safe intratympanic drug delivery.~* Conductive hearing loss \> 20dBHL~* Meniere disease~* Medical history of sudden hearing loss~* Sensoryneural Hearing loss (SNHL) with mean ≥ 40dbHL Pure Tonal Audiometry (PTA)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Standard arm (Arm A): Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)~Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease.
- N-acetylcysteine (Type: EXPERIMENTAL): Experimental arm (Arm B):~* 0.4 to 1 ml of NAC 10% through intratympanic injection (ITI) from 40 to 60 minutes maximum prior to each Cisplatin cycle.~* Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)~Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Preparation Prior to Hysterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing total vaginal, laparoscopic assisted vaginal, total laparoscopic, or robotic-assisted laparoscopic hysterectomy by a physician at Cincinnati Urogynecology Associates or Tri-State Gynecology Oncology TriHealth Inc.~* Concomitant procedures such as vaginal vault suspension, suburethral sling, cystoscopy, enterocele repair, anterior or posterior colporrhaphy, bilateral salpingectomy or salpingooophorectomy, staging procedures, lymph node sampling and other indicated procedures will be included~* English speaking~* Ability to provide consent~Exclusion Criteria:~* Unwillingness to participate in the study~* Non English speaking~* Patients that do not undergo a hysterectomy~* Reported allergy to iodine or chlorhexidine preparation solutions~* Patients undergoing planned debulking surgery for ovarian, fallopian tube or primary peritoneal cancers~* Current infection necessitating hysterectomy~* Active sepsis, pelvic abscess or pelvic inflammatory disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chlorhexidine group (Type: EXPERIMENTAL): None
- Iodine group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues